Key facts
- Notable investors include Lenovo Capital and Incubator Group, Peiyang Begonia Fund, Haihe River Industry Fund, Kunshan Guoke Venture Capital, Apricot Capital (Shanghai) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Zhonghe Gene
- ·The full record, as it builds
Funding rounds
No funding rounds for Zhonghe Gene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zhonghe Gene
Developer of deoxyribonucleic acid (DNA) biosynthesis technology designed to promote the industrial advancement of life sciences research. The company's technology includes its enzymatic DNA synthesis technology, oligo biosynthesis instrument and desktop Kb-level gene synthesizer, providing biological laboratories to achieve breakthroughs in advanced synthetic biological research.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2022
- Employees
- 50
- Website
- zhonghegene.com/
- Ownership
- Privately Held (backing)
Zhonghe Gene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zhonghe Gene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zhonghe Gene in its N-PORT filings yet. We sweep new filings monthly.